Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
His resignation would be effective from March 18, 2024
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Abbott India has reported total income of Rs. 1535 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Subscribe To Our Newsletter & Stay Updated
